The ImmuPharma PLC (IMM) Rating Reiterated by Northland Securities

The ImmuPharma PLC (IMM) Rating Reiterated by Northland Securities

Separately, Panmure Gordon reaffirmed a “buy” rating and issued a GBX 100 ($1.28) price objective on shares of ImmuPharma PLC in a research note on Thursday, April 20th.

ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating reaffirmed by equities researchers at Northland Securities in a research report issued to clients and investors on Thursday. They currently have a GBX 171 ($2.20) price objective on the stock. Northland Securities’ target price would suggest a potential upside of 242.00% from the company’s current price.

Shares of ImmuPharma PLC (LON:IMM) opened at 49.4375 on Thursday. ImmuPharma PLC has a 1-year low of GBX 30.79 and a 1-year high of GBX 70.32. The firm’s market cap is GBX 55.16 million. The firm’s 50-day moving average is GBX 54.09 and its 200-day moving average is GBX 50.53. ImmuPharma PLC Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:IMM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment